1Issemann I and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators [J]. Nature, 1990 :347 : 645 -50.
2Takehiro O,Takashi M,Satoshi S,et al. Stimulation of Peroxisome prolif- erator-activated receptors αattenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts [J]. Clinical Science,2002; 103:284s-8.
3Takehiro O,Takashi M,Satoshi S,et al. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is amelio- rated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate ,partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway [ J ]. J Am Coll Cardiol, 2004 ; 43 : 1481-8.
4Diez C, Nestler M, Friedrich U, et al. Down regulation of Akt/PKB in senescent cardic fibroblasts impairs PDGF-induced cell proliferation[J]. Cardiovase Res,2001 ;49:731-40.
5Khan R, Sheppard R. Fibrosis in heart disease:understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and archythmia[ J ]. Immunology ,2006 ; 118 : 10-24.
6Kuwahara F, Kai H, Tokuda K,et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats [J]. Circulation,2002 ; 106 : 130-5.
7Seeland U, Haeuseler C, Hinrichs R,et al. Myocardial fibrosis in transforming growth factor beta ( 1 ) ( TGF-β1 ) transgenic mice is associated with inhibition of interstitial collagenase[J]. Eur J Clin Invest,2002 ;32 : 295-303.
8Taniyama Y, Morshita R, Nakagami H, et at. Potential contribution of a novel antitibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin Ⅱ blockade in cardiomyopathic hamsters [J]. Circulation ,2000; 102:246-52.
4Schneider S, Yochim J, Brabender J, et al. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer [J]. Clin Cancer Res, 2004, 10(5): 1588--1596.
5Livak K J, Schmittgen TD. Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) Method [J]. Methods, 2001, 25(4):402-408.
6Vera T, Taylor M, Bohman Q, et al. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice [J]. Hypertension, 2005, 45(4) : 730-735.
7Wang Y, Wang Y, Yang Q, et al. Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells[J]. Atherosclerosis, 2006, 187 (2) : 265--273.
8Ichihara S, Obata K, Yamada Y, et al. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors [J]. Mol Cell Cardiol, 2006, 41(2): 318-329.
9Brigadeau F, Gele P, Wibaux M, et al. The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy [J]. J Cardiovasc Pharmacol, 2007, 49(6): 408-415.
10Lebrasseur NK, Duhaney TA, De Silva DS, et al. Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension [J]. Hypertension, 2007, 50(3): 489-496.
